Search Results for keywords:"Medicare Evidence Development

The Judicial Conference of the United States has officially canceled a public hearing that was planned to discuss proposed changes to the Federal Rules of Evidence. This hearing was supposed to take place on February 12, 2025. Information about the cancellation was previously published on July 31, 2024, in the Federal Register. For additional details or questions, people can contact H. Thomas Byron III, Chief Counsel of the Rules Committee Staff.

The Advisory Committee on Evidence Rules is hosting a virtual meeting on April 30, 2021, which is open to the public. People can join by phone or video conference to listen, but not to speak. Information including the agenda will be available online at least seven days before the meeting. For questions, contact Rebecca A. Womeldorf at the Judicial Conference of the United States.

The Judicial Conference of the United States has canceled the public hearing on proposed amendments to the Federal Rules of Evidence that was scheduled for January 22, 2025. The cancellation notice, along with administrative details, was published in the Federal Register. Interested individuals can contact H. Thomas Byron III, Esq., for more information. The original announcement of the hearing was made on July 31, 2024.

The Advisory Committee on Evidence Rules, part of the Judicial Conference of the United States, will be holding a public meeting on April 30, 2021, in Washington, DC. While anyone can observe the meeting, participation is not allowed. Details about the meeting agenda and materials will be available online at least a week before the event. For more information, Rebecca A. Womeldorf serves as the contact person.

The National Cancer Institute (NCI), which is part of the National Institutes of Health (NIH), is considering giving Ziopharm Oncology, Inc. an exclusive patent license to develop and market certain cancer therapies. These therapies involve using a patient's own T cells that are engineered to target specific mutations in the P53 gene, which is commonly mutated in many cancers. The license will cover treatments made through a method known as transposon-mediated gene transfer but will not include those made using CRISPR technology. Interested parties have until February 9, 2021, to submit comments or license applications.

The Department of Education is inviting applications for new awards for the Education Research and Development Center Program for fiscal year 2025. This program aims to fund research centers that will tackle specific educational problems and enhance knowledge in their fields. The department plans to fund projects on topics like improving gifted education and using generative artificial intelligence in higher education. Applications are open from December 20, 2024, with a deadline for submission set on March 14, 2025.

The Department of Education is inviting applications for new awards for the fiscal year 2025 as part of its Indian Education Discretionary Grants Programs. This initiative aims to provide training grants to increase the number of qualified Indian professionals, including teachers and administrators who serve Indian students. The program focuses on supporting pre-service training for teachers and administrators, with specific funding priorities and a competitive preference system for certain applicants, such as Tribal and consortium applications. The total estimated funding available for this competition is $13 million, with awards ranging from $400,000 to $500,000 each.

The World Trade Center (WTC) Health Program has denied four petitions to add amyotrophic lateral sclerosis (ALS) to its list of related health conditions. After reviewing the scientific literature, the Program's Administrator found insufficient evidence to support a causal link between 9/11 exposures and ALS. As a result, the decision was made not to propose adding ALS to the list. This determination was published as a notice on January 22, 2025.

The Securities and Exchange Commission (SEC) is seeking public comments as part of its Paperwork Reduction Act procedures on the reinstatement of a previously approved information collection, which is gathered under rules regarding professional conduct for attorneys. These rules require attorneys practicing before the SEC to report evidence of material violations by an issuer. An alternative procedure allows issuers to create a Qualified Legal Compliance Committee (QLCC) to handle such reports. The SEC estimates that 3% of issuers have or will establish a QLCC, which will result in an annual burden of 692 hours and a cost of $242,200, mainly due to involvement of outside counsel. Public comments on this collection are invited until February 14, 2025.

The Securities and Exchange Commission (SEC) is requesting public comments on information collection related to rules for attorney conduct when representing companies. These rules require attorneys to report evidence of significant violations to the company's higher-ups or the SEC. The SEC aims to reinstate an approved process, which involves creating a legal committee when needed for reporting. The public is invited to comment on the necessity and burden of this reporting by March 31, 2025.